MAPT and Alzheimer disease: Such complaints are considered the first obvious manifestation of the earliest preclinical phase of AD and have been associated with AD biomarkers such as amyloid and tau proteins (Jack et al., 2018; Janssen et al., 2022; Jessen et al., 2023).